Fingolimod @ mg reduced annualized relapse rate by @ % ( P = @ ) versus IFN-@a IM and by @ % ( P < @ ) versus placebo in patients with < @ years since first symptom ; respective reductions were @ % and @ % in subgroups of patients with @ years since first symptom .